Rating Rationale
July 09, 2020 | Mumbai
Bajaj Healthcare Limited
 
Rating Action
Total Bank Loan Facilities Rated Rs.262 Crore
Long Term Rating CRISIL BBB/Positive
Short Term Rating CRISIL A3+
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL's ratings on the bank facilities of Bajaj Healthcare Limited (BHL) continue to reflect BHL's established market position backed by a strong and diversified clientele and a healthy financial risk profile. These strengths are partially offset by exposure to intense competition in the bulk drugs industry and working capital-intensive operations.

On July 7th, 2020, CRISIL had revised its outlook on the long term bank facilities of BHL to 'Positive' from 'Stable' while reaffirming its rating at 'CRISIL BBB'. Short term rating was reaffirmed at 'CRISIL A3+'

Revision in outlook reflects expectation of improvement in business risk profile over the medium term. Healthy demand, better realisations coupled with wider product portfolio through acquisitions and enhanced capacities, should result in higher revenue and profitability. Demand for key products of the company such as Ascorbic acid (Active pharmaceutical ingredient for Vitamin C) and CH Base (raw material for manufacturing sanitiser) have exhibited substantial improvement amidst Covid-19 pandemic. Further. The manufacturing operations were not much impacted by lockdown and other measures taken by central and state governments to contain the spread of the Covid-19, since the company operates in the essential segment. Timely commencement of newly acquired capacities and sustenance of revenue growth and profitability shall remain key rating sensitivity.

Key Rating Drivers & Detailed Description
Strengths: 
* Established market position: The promoters' experience of over 25 years in the bulk drugs industry has resulted in an established relationship with customers and suppliers. Benefits from the established market position, backed by a strong and diversified customer base, should continue. The company has acquired a new plant under distress sale in March 2020 and is in the process of acquiring another unit by the end of September 2020. These additional capacities along with higher demand and realisations for the existing key products are expected support revenue growth and profitability over medium term
 
* Healthy financial risk profile: The networth (adjusted for revaluation reserves) was Rs 112.02 crore, while the total outside liabilities to adjusted networth ratio sustained at 1.5 times as on March 31, 2020. The company is expected to invest around Rs.75-80 crores in fiscal 2020 in acquiring Six manufacturing plant in fiscal 2021 funded by Rs.65 crore debt. Despite the large debt funded acquisition, capital structure is likely to remain healthy with TOLAW ratio expected to be around 1.5-1.6 times over the medium term, on the back of healthy accruals and repayment of existing debt.  The debt protection metrics were robust, with interest coverage ratio over 7 times in fiscal 2020. The financial risk profile is expected to remain healthy over the medium term.
 
Weaknesses:
* Exposure to intense competition in the bulk drugs industry: The industry has a large number of players and fragmented, leading to intense competition. The company is also operates predominantly in the domestic market. This restricts the ability to bargain for better prices with customers in case of escalation in input prices, thus constraining profitability. 
 
* Working capital-intensive operations: Gross current assets were high at around 153 days, driven by inventory of 46 days and receivables cycle of 101 days, as on March 31, 2020. Inventory and receivables are on higher side due to disruptions in sales and collections in March 2020 due to Covid-19 related disruption, likely to improve over the medium term. Credit of 60-90 days is extended to customers and inventory of 40-50 days is maintained. Operations are expected to remain working capital intensive over medium term. The incremental working capital requirement, due to anticipated growth in revenue, and its funding mix are major rating sensitivity factors.
Liquidity Adequate

Net cash accrual of Rs 34.6 crore was adequate to meet debt obligation of around Rs.8.4 crore in fiscal 2020, and is expected at Rs 45-50 crore per annum against debt obligation of Rs 11-12 crore, per fiscal over the medium term. Capex and acquisition is expected at around Rs 75-80 crore in fiscal 2021, funded by term debt of Rs 65 crore. Average bank limit utilisation was 76% during the 12 months through Feb 2020. Expected enhancement in bank lines by around Rs.45 crore would support the incremental working capital requirements over the medium term.

Outlook: Positive

CRISIL believes that the business and financial risk profile of the company is likely improve over the medium term backed by experience of the promoters, favourable demand for key products and new capacities being acquired

Rating Sensitivity factors
Upward factors
* Significant sustainable improvement in revenue and profitability strengthening the business risk profile, leading to improvement net cash accruals to above Rs.45 crores
* Sustenance of healthy financial risk profile especially capital structure and improved debt protection metrics while maintaining the working capital cycle
 
Downward factors
* Subdued revenue growth or decline in operating margins, constraining net cash accruals to below Rs.35 crores
* Stretch in working capital cycle or higher than expected debt funded capex weakens the financial risk profile with TOLANW above 2 times.
About the Company

BHL was incorporated in 1993 as a private limited company by the Bajaj family and was reconstituted as a closely held public limited company in 2005. The company was listed on the SME (small and medium enterprise) segment of the BSE (Bombay Stock Exchange) in May 2016 and later migrated to Main Board of BSE Limited in May 2019. It manufactures active pharmaceutical ingredients and also formulations in the form of tablets, capsules, and powder, and exports bulk drugs to Europe, among other regions.

Key Financial Indicators
As on/for the period ended March 31   2020 2019
Reported income Rs crore 364.7 326
Reported profit after tax Rs crore 22.5 16.3
PAT margins % 6.2 5.0
Adjusted Debt/Adjusted Networth Times 0.81 0.91
Interest coverage Times 7.9 5.29

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments and are included (where applicable) in the Annexure -- Details of Instrument in this Rating Rationale. For more details on the CRISIL complexity levels, please visit www.crisil.com/complexity-levels.
Annexure - Details of Instrument(s)
ISIN Name of Instrument Date of Allotment Coupon
Rate (%)
Complexity
level
Maturity Date Issue Size
(Rs.Cr)
Rating Assigned with Outlook
NA Letter of Credit NA NA NA NA 26.55 CRISIL A3+
NA Post Shipment Credit NA NA NA NA 30 CRISIL A3+
NA Proposed Term Loan NA NA NA NA 45 CRISIL BBB/Positive
NA Proposed Working Capital Facility NA NA NA NA 1 CRISIL BBB/Positive
NA Term Loan NA NA NA Oct-2023 54.45 CRISIL BBB/Positive
NA Working Capital Facility* NA NA NA NA 105 CRISIL BBB/Positive
*Interchangeable between funded and non-fund based facilities
Annexure - Rating History for last 3 Years
  Current 2020 (History) 2019  2018  2017  Start of 2017
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  235.45  CRISIL BBB/Positive/ CRISIL A3+  07-07-20  CRISIL BBB/Positive/ CRISIL A3+  10-06-19  CRISIL BBB/Stable/ CRISIL A3+  04-07-18  CRISIL BBB/Stable/ CRISIL A3+  13-12-17  CRISIL BBB/Stable/ CRISIL A3+  CRISIL BBB/Stable/ CRISIL A3+ 
Non Fund-based Bank Facilities  LT/ST  26.55  CRISIL A3+  07-07-20  CRISIL A3+  10-06-19  CRISIL A3+  04-07-18  CRISIL A3+  13-12-17  CRISIL A3+  CRISIL A3+ 
All amounts are in Rs.Cr.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Letter of Credit 26.55 CRISIL A3+ Letter of Credit 26.55 CRISIL A3+
Post Shipment Credit 30 CRISIL A3+ Post Shipment Credit 30 CRISIL A3+
Proposed Term Loan 45 CRISIL BBB/Positive Proposed Term Loan 45 CRISIL BBB/Positive
Proposed Working Capital Facility 1 CRISIL BBB/Positive Proposed Working Capital Facility 56 CRISIL BBB/Positive
Term Loan 54.45 CRISIL BBB/Positive Term Loan 54.45 CRISIL BBB/Positive
Working Capital Facility* 105 CRISIL BBB/Positive Working Capital Facility* 50 CRISIL BBB/Positive
Total 262 -- Total 262 --
*Interchangeable between funded and non-fund based facilities
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
Rating Criteria for the Pharmaceutical Industry
CRISILs Criteria for rating short term debt

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Rahul Guha
Director - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8320
rahul.guha@crisil.com


Jumana Badshah
Associate Director - CRISIL Ratings
CRISIL Limited
D:+91 22 3342 8324
Jumana.Badshah@crisil.com


Athul Sreelatha
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 22 3342 3046
Athul.Sreelatha@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL